75 related articles for article (PubMed ID: 36281591)
21. Treatment of patients with unresectable advanced carcinoma of biliary tract - chemotherapy and surgical resection.
Morise Z; Sugioka A; Tanahashi Y; Okabe Y; Ikeda M; Kagawa T; Takeura C
Anticancer Res; 2009 May; 29(5):1783-6. PubMed ID: 19443404
[TBL] [Abstract][Full Text] [Related]
22. [Current aspects of chemotherapy of metastatic pancreatic and biliary tract carcinomas].
Bokemeyer C; Kollmannsberger C; Oettle H; Kanz L
Praxis (Bern 1994); 2000 Sep; 89(39):1545-52. PubMed ID: 11068508
[TBL] [Abstract][Full Text] [Related]
23. FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue.
Rizzo A; Ricci AD; Frega G; Di Federico A; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):567-574. PubMed ID: 33787429
[No Abstract] [Full Text] [Related]
24. Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling.
Silverman IM; Li M; Murugesan K; Krook MA; Javle MM; Kelley RK; Borad MJ; Roychowdhury S; Meng W; Yilmazel B; Milbury C; Shewale S; Feliz L; Burn TC; Albacker LA
J Mol Diagn; 2022 Apr; 24(4):351-364. PubMed ID: 35176488
[TBL] [Abstract][Full Text] [Related]
25. Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments.
Valery M; Vasseur D; Fachinetti F; Boilève A; Smolenschi C; Tarabay A; Antoun L; Perret A; Fuerea A; Pudlarz T; Boige V; Hollebecque A; Ducreux M
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760415
[TBL] [Abstract][Full Text] [Related]
26. Changing Landscape of Systemic Therapy in Biliary Tract Cancer.
Woods E; Le D; Jakka BK; Manne A
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565266
[TBL] [Abstract][Full Text] [Related]
27. Treating Biliary Tract Cancers: New Targets and Therapies.
Ho J; Fiocco C; Spencer K
Drugs; 2022 Nov; 82(17):1629-1647. PubMed ID: 36441502
[TBL] [Abstract][Full Text] [Related]
28. Intrahepatic cholangiocarcinoma with FGFR2 fusion gene positive that responded to pemigatinib and caused hypophosphatemia.
Kikuchi Y; Yamaguchi K; Shimizu R; Matsumoto Y; Kurose Y; Okano N; Otsuka Y; Shibuya K; Matsuda T; Shimada H
Int Cancer Conf J; 2023 Oct; 12(4):285-290. PubMed ID: 37577338
[TBL] [Abstract][Full Text] [Related]
29. Paradigm shift of chemotherapy and systemic treatment for biliary tract cancer.
Leowattana W; Leowattana T; Leowattana P
World J Gastrointest Oncol; 2023 Jun; 15(6):959-972. PubMed ID: 37389105
[TBL] [Abstract][Full Text] [Related]
30. Build to understand biliary oncogenesis via organoids and FGFR2 fusion proteins.
Boulter L; Ebrahimkhani MR
J Hepatol; 2021 Aug; 75(2):262-264. PubMed ID: 34029636
[No Abstract] [Full Text] [Related]
31. Second-line FOLFOX is not the standard of care for all patients with advanced biliary tract cancer-a commentary from the Young International Society of Geriatric Oncology.
Liposits G; Arora SP; Battisti NML; Soto-Perez-de-Celis E; Loh KP; Williams GR
Ann Oncol; 2023 Jun; 34(6):555-556. PubMed ID: 36813114
[No Abstract] [Full Text] [Related]
32. Adjuvant therapy in biliary tract cancers: oral fluoropyrimidine as a beginning.
Chiang NJ; Chen LT
Lancet; 2023 Jan; 401(10372):170-171. PubMed ID: 36681404
[No Abstract] [Full Text] [Related]
33. Capecitabine: Still a Standard Option in the Adjuvant Setting of Biliary Tract Cancer?
Edeline J; Malka D
J Clin Oncol; 2022 Nov; 40(31):3667-3668. PubMed ID: 35786978
[No Abstract] [Full Text] [Related]
34. Clinical experience with pemigatinib for previously treated metastatic cholangiocarcinoma: practical considerations from clinical cases.
Wadsley J; Christie A; Gillmore R; Trinh A; Greig R
Drugs Context; 2023; 12():. PubMed ID: 37602357
[TBL] [Abstract][Full Text] [Related]
35. Outcome of second-line chemotherapy for biliary tract cancer.
Bridgewater J; Palmer D; Cunningham D; Iveson T; Gillmore R; Waters J; Harrison M; Wasan H; Corrie P; Valle J
Eur J Cancer; 2013 Apr; 49(6):1511. PubMed ID: 23265701
[No Abstract] [Full Text] [Related]
36. [Genes and pathways: FGFR2 translocations and gene fusion analysis].
Neumann O; Ball M; Lehmann U; Schirmacher P; Stenzinger A; Kazdal D
Pathologie (Heidelb); 2022 Sep; 43(5):384-386. PubMed ID: 35925311
[No Abstract] [Full Text] [Related]
37. [Biliary tract cancers: new medical therapeutic approaches guided by molecular data].
Delaye M; Neuzillet C
Ann Pathol; 2022 Dec; 42(6S):6S8-6S10. PubMed ID: 36577542
[No Abstract] [Full Text] [Related]
38. [Cancer Therapy Targeting Fusion Gene(FGFR2 Fusion Gene)in Biliary Tract Cancer].
Hamaguchi T; Ueno M
Gan To Kagaku Ryoho; 2022 Oct; 49(10):1040-1042. PubMed ID: 36281591
[TBL] [Abstract][Full Text] [Related]
39. Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers.
Boilève A; Verlingue L; Hollebecque A; Boige V; Ducreux M; Malka D
Expert Opin Investig Drugs; 2021 Apr; 30(4):401-409. PubMed ID: 33641556
[No Abstract] [Full Text] [Related]
40. New developments in systemic therapy for advanced biliary tract cancer.
Morizane C; Ueno M; Ikeda M; Okusaka T; Ishii H; Furuse J
Jpn J Clin Oncol; 2018 Aug; 48(8):703-711. PubMed ID: 29893894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
